BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy (original) (raw)

Guidelines for the use of anti-TNF therapies in rheumatoid arthritis (RA) have evolved significantly due to the advancement of treatment options and growing safety concerns. This article reviews the updated eligibility criteria set forth by the British Society for Rheumatology (BSR) regarding the treatment of RA with first-generation and newly licensed second-generation anti-TNF agents. Emphasis is placed on the continuous collection of safety and efficacy data through clinical studies and registries, highlighting the need for clinicians to stay informed in this rapidly changing area of practice.